---
title: "Edesa Biotech | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286467069.md"
datetime: "2026-05-14T20:53:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286467069.md)
  - [en](https://longbridge.com/en/news/286467069.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286467069.md)
---

# Edesa Biotech | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.49, missing the estimate of USD -0.26.

EBIT: As of FY2026 Q2, the actual value is USD -4.297 M.

The provided Form 8-K for Edesa Biotech, Inc. announces the issuance of a press release on May 14, 2026, detailing financial results for the three and six months ended March 31, 2026 . However, the actual financial results, operational metrics, or any forward-looking guidance are not included within the text of this Form 8-K itself . Therefore, no specific financial or operational metrics can be extracted from the provided reference .

### Related Stocks

- [EDSA.US](https://longbridge.com/en/quote/EDSA.US.md)

## Related News & Research

- [ERG announces availability of H1 2026 interim financial report](https://longbridge.com/en/news/294572882.md)
- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [Anglogold Ashanti Says Guidance On Track With An Improved H2 2026](https://longbridge.com/en/news/294511455.md)
- [Ciena's Q3 2026 Earnings: What to Expect](https://longbridge.com/en/news/293952665.md)
- [Vale updates financial events calendar for 2026](https://longbridge.com/en/news/294418484.md)